JP2012509264A5 - - Google Patents

Download PDF

Info

Publication number
JP2012509264A5
JP2012509264A5 JP2011536397A JP2011536397A JP2012509264A5 JP 2012509264 A5 JP2012509264 A5 JP 2012509264A5 JP 2011536397 A JP2011536397 A JP 2011536397A JP 2011536397 A JP2011536397 A JP 2011536397A JP 2012509264 A5 JP2012509264 A5 JP 2012509264A5
Authority
JP
Japan
Prior art keywords
polymer
lactide
weight
ester
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011536397A
Other languages
English (en)
Japanese (ja)
Other versions
JP5580832B2 (ja
JP2012509264A (ja
Filing date
Publication date
Priority claimed from US12/272,548 external-priority patent/US9095506B2/en
Application filed filed Critical
Publication of JP2012509264A publication Critical patent/JP2012509264A/ja
Publication of JP2012509264A5 publication Critical patent/JP2012509264A5/ja
Application granted granted Critical
Publication of JP5580832B2 publication Critical patent/JP5580832B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011536397A 2008-11-17 2009-11-06 生分解性α−2アゴニストポリマー性インプラントおよびその治療用途 Expired - Fee Related JP5580832B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/272,548 US9095506B2 (en) 2008-11-17 2008-11-17 Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US12/272,548 2008-11-17
PCT/US2009/063490 WO2010056598A2 (en) 2008-11-17 2009-11-06 Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014143227A Division JP2014184348A (ja) 2008-11-17 2014-07-11 生分解性α−2アゴニストポリマー性インプラントおよびその治療用途

Publications (3)

Publication Number Publication Date
JP2012509264A JP2012509264A (ja) 2012-04-19
JP2012509264A5 true JP2012509264A5 (enExample) 2012-12-20
JP5580832B2 JP5580832B2 (ja) 2014-08-27

Family

ID=41698087

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011536397A Expired - Fee Related JP5580832B2 (ja) 2008-11-17 2009-11-06 生分解性α−2アゴニストポリマー性インプラントおよびその治療用途
JP2014143227A Pending JP2014184348A (ja) 2008-11-17 2014-07-11 生分解性α−2アゴニストポリマー性インプラントおよびその治療用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014143227A Pending JP2014184348A (ja) 2008-11-17 2014-07-11 生分解性α−2アゴニストポリマー性インプラントおよびその治療用途

Country Status (7)

Country Link
US (7) US9095506B2 (enExample)
EP (1) EP2355795B1 (enExample)
JP (2) JP5580832B2 (enExample)
AU (3) AU2009314266A1 (enExample)
CA (1) CA2743837C (enExample)
ES (1) ES2624448T3 (enExample)
WO (1) WO2010056598A2 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CA2762536C (en) 2009-05-18 2019-05-21 Dose Medical Corporation Drug eluting ocular implant
AU2010256558B2 (en) 2009-06-03 2013-10-03 Forsight Labs, Llc Anterior segment drug delivery
CA2780267C (en) 2009-11-09 2020-06-30 Allergan, Inc. Compositions and methods for stimulating hair growth
CN102821753A (zh) 2010-01-22 2012-12-12 阿勒根公司 前房内持续释放治疗药植入物
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
US20120213840A1 (en) * 2011-02-18 2012-08-23 Valeant International (Barbados) Srl Ocular strips
EP3967297A1 (en) 2011-04-29 2022-03-16 Allergan, Inc. Sustained release latanoprost implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
RU2740680C2 (ru) 2011-09-14 2021-01-19 Форсайт Вижн5, Инк. Глазное вкладочное устройство и способы
US20180126033A9 (en) 2012-03-14 2018-05-10 MAM Holdings of West Florida, L.L.C. Collagen compositions and uses for biomaterial implants
CA2867203C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
JP5883539B2 (ja) 2012-03-16 2016-03-15 ザ・ジョンズ・ホプキンス・ユニバーシティー Hif−1阻害剤の送達のための放出制御製剤
ES2752028T3 (es) 2012-10-26 2020-04-02 Forsight Vision5 Inc Sistema oftálmico para la liberación sostenida del fármaco en el ojo
AU2014216112B2 (en) * 2013-02-15 2019-02-21 Allergan, Inc. Sustained drug delivery implant
BR112015025915A8 (pt) 2013-04-12 2020-01-14 Allergan Inc uso de composto para redução de gordura e composições
HUE050902T2 (hu) 2013-10-31 2021-01-28 Allergan Inc Prosztamidot tartalmazó intraokuláris implantátumok és azok alkalmazási módszerei
JP6546194B2 (ja) * 2013-12-06 2019-07-17 アラーガン、インコーポレイテッドAllergan,Incorporated 眼性状態を処置するための前房内インプラント
EA201692402A1 (ru) * 2014-05-23 2017-03-31 Окьюлар Текнолоджис Сарл Лекарственные формы для местного применения и их использование
JP6655610B2 (ja) 2014-05-29 2020-02-26 グローコス コーポレーション 制御された薬物送達機能を備えるインプラント及びそれを使用する方法
US10172852B2 (en) 2014-07-28 2019-01-08 Sun Pharma Advanced Research Company Ltd. Method of increasing bioavailability and/or prolonging ophthalmic action of a drug
CN106794152A (zh) 2014-08-13 2017-05-31 约翰霍普金斯大学 用于预防角膜同种异体移植物排斥和新生血管形成的载有糖皮质激素的纳米颗粒
NZ733130A (en) 2014-12-15 2018-09-28 Univ Johns Hopkins Sunitinib formulations and methods for use thereof in treatment of ocular disorders
CN107206099A (zh) 2015-01-20 2017-09-26 约翰霍普金斯大学 用于持续释放抗青光眼剂以控制眼内压的组合物
EP3265165B1 (en) 2015-03-06 2020-08-19 Aerie Pharmaceuticals, Inc. Implant applicators
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
EP3324944A4 (en) * 2015-07-23 2019-04-03 Aerie Pharmaceuticals, Inc. INTRAVITREAL AGGREGATION SYSTEMS FOR THE TREATMENT OF EYE DISEASE
JP6856620B2 (ja) * 2015-07-27 2021-04-07 サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドSun Pharma Advanced Research Company Limited 薬剤搭載ナノ樹脂粒子
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
CN114469872A (zh) 2015-11-12 2022-05-13 灰色视觉公司 用于治疗的聚集性微粒
US9579350B1 (en) 2016-02-25 2017-02-28 MAM Holdings of West Florida, L.L.C. Human amniotic fluid preparation having long-term stability
US20190022016A1 (en) 2016-03-02 2019-01-24 The Johns Hopkins University Compositions for sustained release of anti-glaucoma agents to control intraocular pressure
JP7003110B2 (ja) 2016-04-20 2022-01-20 ドーズ メディカル コーポレーション 生体吸収性眼球薬物送達デバイス
EP3506863A4 (en) 2016-09-02 2020-04-29 Envisia Therapeutics Inc. IMPLANT APPLICATORS
EP3600324A4 (en) 2017-03-23 2020-12-09 Graybug Vision, Inc. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS
RU2019139817A (ru) 2017-05-10 2021-06-10 Грейбуг Вижн, Инк. Микрочастицы с замедленным высвобождением и их суспензии для лекарственной терапии
CN111432807A (zh) 2017-10-06 2020-07-17 铸造疗法股份有限公司 用于控制释放治疗剂的可植入贮库
CN111655303A (zh) 2018-01-08 2020-09-11 铸造疗法股份有限公司 经由治疗剂的控制递送用于治疗腔内癌症的装置、系统和方法
AU2019270779B2 (en) 2018-05-12 2024-08-01 Foundry Therapeutics, Inc. Implantable depots for the controlled release of therapeutic agents
AU2019294615A1 (en) * 2018-06-25 2021-02-11 ReacX Pharmaceuticals, Inc. Implants for release of lipophilic or amphiphilic pharmaceutical substances
WO2020047013A1 (en) 2018-08-28 2020-03-05 Foundry Therapeutics, Inc. Polymer implants
BR112021017436A2 (pt) 2019-03-05 2021-11-16 Aerie Pharmaceuticals Inc Composições farmacêuticas para tratamento de doenças ou transtornos oculares
CA3184991A1 (en) 2020-07-21 2022-01-27 Alazar N. Ghebremeskel Intraocular implant with high loading of a prostamide
WO2024074585A2 (en) 2022-10-05 2024-04-11 Mireca Medicines Gmbh MICROPARTICLE AND IMPLANT FORMULATIONS FOR cGMP ANALOG THERAPY
WO2025179071A1 (en) * 2024-02-20 2025-08-28 Bausch + Lomb Ireland Limited Sustained-release drug delivery compositions for treating ocular diseases

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054102A (en) 1936-09-15 Voting machine
NL64744C (enExample) 1940-03-09
US2401708A (en) 1943-01-19 1946-06-04 Eastman Kodak Co Range finder
US2401408A (en) 1944-05-03 1946-06-04 Harold S Bixby Lock for fluorescent lamps
US2743837A (en) 1953-06-01 1956-05-01 Leon J Cook Lead sleeve expanding device
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
JPS58126435U (ja) 1982-02-19 1983-08-27 オリンパス光学工業株式会社 Ttlオ−トストロボ用絞り制御回路
US4521210A (en) 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5264188A (en) 1991-01-22 1993-11-23 Phillips Petroleum Company Multi-stage hydrotreating process and apparatus
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5856329A (en) 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
WO1998010758A1 (en) 1996-09-13 1998-03-19 The Regents Of The University Of California Methods for treatment of retinal diseases
KR20010014384A (ko) 1997-07-02 2001-02-26 모리타 다카카즈 폴리락트산 공막 플러그
WO1999007418A2 (en) 1997-08-11 1999-02-18 Allergan Sales, Inc. Sterile bioerodible implant device with improved biocompatability and method
DE60018777T2 (de) 1999-10-21 2006-02-02 Alcon Inc. Medikamentenversorgung der sub-tenon
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US20010049369A1 (en) * 2000-02-10 2001-12-06 Jablonski Monica M. Brimonidine compositions and methods for retinal degeneration
US6692759B1 (en) 2000-06-28 2004-02-17 The Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
WO2002058730A2 (en) 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
DE60114229T2 (de) 2000-11-29 2006-07-06 Allergan, Inc., Irvine Verhinderung von transplantatabstossung im auge
CA2466642C (en) 2001-11-14 2011-01-18 Guohua Chen Injectable depot composition
CN1313155C (zh) 2002-03-18 2007-05-02 诺瓦提斯公司 包含环果聚糖、载体和药物的局部用组合物
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
JP4463681B2 (ja) 2002-07-15 2010-05-19 アルコン,インコーポレイテッド 眼内使用のための非ポリマー親油性薬学的インプラント組成物
US6899717B2 (en) 2002-09-18 2005-05-31 Allergan, Inc. Methods and apparatus for delivery of ocular implants
HK1080408B (en) * 2002-10-08 2008-08-08 Allergan, Inc. Use of brimonidine in the treatment of dementia and parkinsons disease
DE60325511D1 (de) 2002-11-06 2009-02-05 Alza Corp Depot-formulierungen mit verzögerter freisetzung
AU2004207506B2 (en) 2003-01-24 2009-10-08 Psivida Us Inc. Sustained release device and method for ocular delivery of adrenergic agents
JP2005035235A (ja) * 2003-07-18 2005-02-10 Noritsu Koki Co Ltd 画像露光装置
US20050131372A1 (en) * 2003-12-10 2005-06-16 Kimberly-Clark Worldwide, Inc. Absorbent articles with removable protective wing portions
US20060182781A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244458A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US20050244471A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7135391B2 (en) * 2004-05-21 2006-11-14 International Business Machines Corporation Polycrystalline SiGe junctions for advanced devices
US7931909B2 (en) * 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
EP3959399B1 (en) 2019-04-23 2023-03-15 Raily S.r.l. Modular railing suitable for variable installation slopes
US11902105B2 (en) 2022-05-24 2024-02-13 Red Hat, Inc. Interactive graphical user interface for visualizing flow data in a programmable network switch

Similar Documents

Publication Publication Date Title
JP2012509264A5 (enExample)
WO2011109384A3 (en) Biodegradable polymers for lowering intraocular pressure
JP2010507451A5 (enExample)
JP2009532087A5 (enExample)
EA201170039A1 (ru) Полимерные частицы, нагруженные лекарственным средством, и способы их получения и применения
JP2013518049A5 (enExample)
WO2012054923A3 (en) Therapeutic nanoparticles with high molecular weight copolymers
JP2011525514A5 (enExample)
JP7500659B2 (ja) 架橋粒子
JP2012528154A5 (enExample)
WO2011151356A3 (en) Methods for the preparation of injectable depot compositions
JP2018502956A5 (enExample)
JP2010537989A5 (enExample)
JP2012528155A5 (enExample)
JP2015508118A5 (enExample)
WO2011091205A3 (en) Intracameral sustained release therapeutic agent implants
JP2019512006A5 (enExample)
JP2010528136A5 (enExample)
JP2007297460A5 (enExample)
JP2011511874A5 (enExample)
CN103055354B (zh) 一种生物可降解的医用手术防粘连膜及其制备方法
CN1665889A (zh) 具有经提高的耐水性的生物降解性组合物及其制作工艺
JP2018503736A5 (enExample)
CN101050243A (zh) 一种两亲性壳聚糖衍生物及其制备方法和在药剂学中的应用
Bramfeldt et al. Characterization, degradation, and mechanical strength of poly (D, L‐lactide‐co‐ϵ‐caprolactone)‐poly (ethylene glycol)‐poly (D, L‐lactide‐co‐ϵ‐caprolactone)